Single versus dual blockade of the renin-angiotensin system in patients with IgA nephropathy

• DOI: 10.1007/s40620-020-00836-8
• Publication Date: 2020-08-27T16:04:46Z
• Authors: David Paul Lennartz; Claudia Seikrit; Stephanie Wied; Christina Fitzner; Frank Eitner; Ralf-Dieter Hilgers; Thomas Rauen; Jürgen Floege
• Keywords: Nephrology

Abstract Background Inhibitors of the renin-angiotensin system (RAS) are cornerstones supportive therapy in patients with IgA nephropathy (IgAN). We analyzed effects single versus dual RAS blockaQueryde during our randomized STOP-IgAN trial. Methods participants available successive information on their treatment regimen and renal outcomes 3-year trial phase were stratified post hoc into two groups, i.e. under continuous or blocker over entire 3 years phase. Primary secondary endpoints, frequencies full clinical remission, eGFR-loss ≥ 15 30 ml/min/1.73 m 2 ESRD onset, by logistic regression linear mixed models. Results Among 112 included present analysis, 82 (73%) maintained (27%) inhibitor throughout Neither strategy significantly affected rates, onset ESRD. Proteinuria moderately increased blockade 0.1 g/g creatinine This was particularly evident without additional immunosuppression phase, where proteinuria 0.2 group. In contrast, decreased 0.3 creatinine. The course eGFR remained stable did not differ between strategies. Conclusion cohort, neither altered outcomes. Patients even exhibited higher